| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Joshua D Rosenblat, Shakila Meshkat, Zoe Doyle, Erica Kaczmarek, Ryan M Brudner, Kevin Kratiuk, Rodrigo B Mansur, Christian Schulz-Quach, Rickinder Sethi, Amanda Abate, Shaun Ali, Jordan Bawks, Marc G Blainey, Elisa Brietzke, Victoria Cronin, Jessica Danilewitz, Shalini Dhawan, Anthony Di Fonzo, Melissa Di Fonzo, Pawel Drzadzewski, William Dunlop, Hajnalka Fiszter, Fabiano A Gomes, Smrita Grewal, Marisa Leon-Carlyle, Marilyn McCallum, Niki Mofidi, Hilary Offman, Jeremy Riva-Cambrin, Joel Schmidt, Mark Smolkin, Joan M Quinn, Andrea Zumrova, Michelle Marlborough, Roger S McIntyr. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med (New York, N.Y.). 2024-02-15. PMID:38359838. |
psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin. |
2024-02-15 |
2024-02-18 |
human |
| Scott T Aaronson, Zofia Koza. New evidence for flexible psilocybin dosing in patients with treatment-resistant depression. Med (New York, N.Y.). 2024-02-15. PMID:38359837. |
new evidence for flexible psilocybin dosing in patients with treatment-resistant depression. |
2024-02-15 |
2024-02-18 |
Not clear |
| Scott T Aaronson, Zofia Koza. New evidence for flexible psilocybin dosing in patients with treatment-resistant depression. Med (New York, N.Y.). 2024-02-15. PMID:38359837. |
psilocybin has demonstrated efficacy for treating depression; however, psychiatrically complex patients have been excluded from trials. |
2024-02-15 |
2024-02-18 |
Not clear |
| Tommaso Barba, Hannes Kettner, Caterina Radu, Joseph M Peill, Leor Roseman, David J Nutt, David Erritzoe, Robin Carhart-Harris, Bruna Giribald. Psychedelics and sexual functioning: a mixed-methods study. Scientific reports. vol 14. issue 1. 2024-02-07. PMID:38326446. |
convergent results were found in a controlled trial of psilocybin therapy versus an ssri, escitalopram, for depression. |
2024-02-07 |
2024-02-10 |
human |
| Joost J Breeksema, Alistair Niemeijer, Erwin Krediet, Tilman Karsten, Jeanine Kamphuis, Eric Vermetten, Wim van den Brink, Robert Schoever. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Scientific reports. vol 14. issue 1. 2024-02-05. PMID:38316896. |
patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. |
2024-02-05 |
2024-02-09 |
Not clear |
| Joost J Breeksema, Alistair Niemeijer, Erwin Krediet, Tilman Karsten, Jeanine Kamphuis, Eric Vermetten, Wim van den Brink, Robert Schoever. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Scientific reports. vol 14. issue 1. 2024-02-05. PMID:38316896. |
psilocybin is the most researched classic psychedelic for treatment-resistant depression (trd). |
2024-02-05 |
2024-02-09 |
Not clear |
| Tessa Watford, Naqash Masoo. Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 22. issue 1. 2024-01-22. PMID:38247407. |
with this, psilocybin could prove to be revolutionary in treating depression and become an alternative medication to ssris. |
2024-01-22 |
2024-01-24 |
human |
| Balázs Szigeti, Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt, Robin Carhart-Harri. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychological medicine. 2024-01-22. PMID:38247730. |
assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. |
2024-01-22 |
2024-01-24 |
Not clear |
| Sabrina Wong, Angela T H Kwan, Kayla M Teopiz, Gia Han Le, Shakila Meshkat, Roger Ho, Giacomo d'Andrea, Bing Cao, Joshua D Di Vincenzo, Joshua D Rosenblat, Roger S McIntyr. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Journal of affective disorders. 2024-01-20. PMID:38244804. |
a comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (nnt): a systematic review. |
2024-01-20 |
2024-01-23 |
Not clear |
| Sabrina Wong, Angela T H Kwan, Kayla M Teopiz, Gia Han Le, Shakila Meshkat, Roger Ho, Giacomo d'Andrea, Bing Cao, Joshua D Di Vincenzo, Joshua D Rosenblat, Roger S McIntyr. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Journal of affective disorders. 2024-01-20. PMID:38244804. |
esketamine is a proven treatment recently approved for adults with treatment-resistant depression (trd) while psilocybin is an investigational treatment. |
2024-01-20 |
2024-01-23 |
Not clear |
| Fatima Iftikhar Shah, Somia Shehzadi, Fatima Akram, Ikram Ul Haq, Benish Javed, Sadeed Sabir, Yasha Kazim, Sehrish Ashfa. Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy. Molecular biotechnology. 2023-12-20. PMID:38117395. |
this comprehensive review explores psilocybin, derived from specific mushrooms, and its implications in the treatment of depression. |
2023-12-20 |
2023-12-23 |
Not clear |
| Nicholas Kolbman, Tiecheng Liu, Peter Guzzo, Jim Gilligan, George A Mashour, Giancarlo Vanini, Dinesh Pa. Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain. Current biology : CB. vol 33. issue 24. 2023-12-19. PMID:38113836. |
in particular, psilocybin has shown promise for the treatment of refractory depression |
2023-12-19 |
2023-12-23 |
rat |
| Scott T Aaronson, Andrew van der Vaart, Tammy Miller, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Harold A Sackeim, Trisha Suppe. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial. JAMA psychiatry. 2023-12-06. PMID:38055270. |
psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression. |
2023-12-06 |
2023-12-10 |
Not clear |
| James J Gattuso, Carey Wilson, Anthony J Hannan, Thibault Renoi. Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review. Journal of neurochemistry. 2023-11-29. PMID:38019032. |
psilocybin has begun to show efficacy for a range of neuropsychiatric conditions, including treatment-resistant depression and anxiety disorders; however, neurobiological mechanisms are still being elucidated. |
2023-11-29 |
2023-12-07 |
human |
| James J Gattuso, Carey Wilson, Anthony J Hannan, Thibault Renoi. Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review. Journal of neurochemistry. 2023-11-29. PMID:38019032. |
we found that psilocybin shows promise as a lead candidate molecule for treating a variety of neuropsychiatric conditions, albeit showing the most efficacy for depression. |
2023-11-29 |
2023-12-07 |
human |
| Huda Ahmed, Hasan Mushahid, Talal Arsha. UNCOVERING THE UNTAPPED POTENTIAL OF PSILOCYBIN THERAPY IN ALLEVIATING CANCER-RELATED DEPRESSION: AN URGENT CALL TO RE-EVALUATE TREATMENT STRATEGIES. Psychiatria Danubina. vol 35. issue 4. 2023-11-24. PMID:37992112. |
uncovering the untapped potential of psilocybin therapy in alleviating cancer-related depression: an urgent call to re-evaluate treatment strategies. |
2023-11-24 |
2023-11-28 |
Not clear |
| Elizabeth Boudreau, Krissa Orlowsk. Psilocybin therapy to reduce depression following a terminal diagnosis. JAAPA : official journal of the American Academy of Physician Assistants. vol 36. issue 12. 2023-11-21. PMID:37989175. |
psilocybin therapy to reduce depression following a terminal diagnosis. |
2023-11-21 |
2023-11-29 |
Not clear |
| Sheetal A Raithatha, Jillian M Hagel, Kaveh Matinkhoo, Lisa Yu, David Press, Sarah G Cook, Govinda Sharma, D Dhananjaya, Glynnis Jensen, Jessica B Lee, Charlie Cai, Jonathan Gallant, Jaideep Bains, Joseph E Tucker, Peter J Facchin. Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders. Journal of medicinal chemistry. 2023-11-20. PMID:37983270. |
despite positive clinical end points targeting depression and anxiety, concerns regarding the duration of the psychedelic experience produced by psilocybin, associated with enduring systemic exposure to the active metabolite psilocin, pose a barrier to its therapeutic application. |
2023-11-20 |
2023-11-29 |
Not clear |
| Anees Bahji, Isis Lunsky, Gilmar Gutierrez, Gustavo Vazque. Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. Journal of psychoactive drugs. 2023-11-16. PMID:37968944. |
eighteen studies were identified, which suggested that psychedelic therapies were well tolerated and presented a large effect size for the management of depression symptoms in a transdiagnostic population with psilocybin (g = -1.92, 95% ci, -2.73 to -1.11) and mdma (g = -0.71; 95% ci, -1.39 to -0.03). |
2023-11-16 |
2023-11-20 |
Not clear |
| D J Nutt, J M Peill, B Weiss, K Godfrey, R L Carhart-Harris, D Erritzo. Psilocybin and Other Classic Psychedelics in Depression. Current topics in behavioral neurosciences. 2023-11-13. PMID:37955822. |
psilocybin and other classic psychedelics in depression. |
2023-11-13 |
2023-11-20 |
Not clear |